Compare Stocks: ANL, AKBA, SIGA, and AEON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.16 +1.4%	$0.25	$0.13 ▼ $1.45	$8.03M	0.68	2.68 million shs	73,494 shs
AKBA Akebia Therapeutics	$0.48 -3.0%	$0.78	$0.36 ▼ $1.84	$134.11M	0.24	5.21 million shs	715,951 shs
ANL Adlai Nortye	$10.14 -3.6%	$13.11	$0.88 ▼ $17.25	$653.02M	1.36	357,997 shs	41,848 shs
SIGA Siga Technologies	$2.85 -1.6%	$3.18	$2.83 ▼ $7.11	$204.44M	1.1	602,182 shs	28,787 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	-7.41%	+0.38%	-30.91%	-42.31%	-82.59%
AKBA Akebia Therapeutics	-13.20%	+17.04%	-35.32%	-43.69%	-73.08%
ANL Adlai Nortye	-3.04%	+8.68%	-10.54%	-20.60%	+553.46%
SIGA Siga Technologies	-7.96%	-2.69%	-6.17%	-3.67%	-53.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.16 +1.4%	$0.25	$0.13 ▼ $1.45	$8.03M	0.68	2.68 million shs	73,494 shs
AKBA Akebia Therapeutics	$0.48 -3.0%	$0.78	$0.36 ▼ $1.84	$134.11M	0.24	5.21 million shs	715,951 shs
ANL Adlai Nortye	$10.14 -3.6%	$13.11	$0.88 ▼ $17.25	$653.02M	1.36	357,997 shs	41,848 shs
SIGA Siga Technologies	$2.85 -1.6%	$3.18	$2.83 ▼ $7.11	$204.44M	1.1	602,182 shs	28,787 shs

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	-7.41%	+0.38%	-30.91%	-42.31%	-82.59%
AKBA Akebia Therapeutics	-13.20%	+17.04%	-35.32%	-43.69%	-73.08%
ANL Adlai Nortye	-3.04%	+8.68%	-10.54%	-20.60%	+553.46%
SIGA Siga Technologies	-7.96%	-2.69%	-6.17%	-3.67%	-53.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	2.75	Moderate Buy	$1.67	935.20% Upside
AKBA Akebia Therapeutics	2.43	Hold	$3.90	707.45% Upside
ANL Adlai Nortye	2.86	Moderate Buy	$29.50	190.93% Upside
SIGA Siga Technologies	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ANL, AKBA, SIGA, and AEON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/4/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D)
10/12/2026	ANL Adlai Nortye	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/5/2026	ANL Adlai Nortye	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/2/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/1/2026	AEON AEON Biopharma	Lake Street Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$1.00 ➝ $2.00
9/16/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/15/2026	AKBA Akebia Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$4.00
9/10/2026	ANL Adlai Nortye	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$31.00
9/9/2026	AEON AEON Biopharma	Laidlaw Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$1.80
9/8/2026	ANL Adlai Nortye	Loop Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$49.00
9/8/2026	AKBA Akebia Therapeutics	Westpark Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$4.50

(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
AKBA Akebia Therapeutics	$197.20M	0.68	N/A	N/A	$0.07 per share	6.90
ANL Adlai Nortye	$5M	130.60	N/A	N/A	($0.21) per share	-48.29
SIGA Siga Technologies	$94.57M	2.16	$0.30 per share	9.43	$2.27 per share	1.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	-$4.42	0.89	N/A	N/A	N/A	N/A	-994.63%	11/13/2026 (Estimated)
AKBA Akebia Therapeutics	-$5.34M	-$0.16	N/A	N/A	N/A	-22.60%	-156.59%	-11.53%	N/A
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	$23.28M	N/A	N/A	N/A	N/A	1.31%	0.40%	0.35%	N/A

Latest ANL, AKBA, SIGA, and AEON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	N/A	AEON AEON Biopharma	-$0.10	N/A	N/A	N/A	N/A	N/A
11/9/2026	Q3 2026	SIGA Siga Technologies	N/A	-$0.04	N/A	-$0.04	N/A	$1.32 million
11/5/2026	Q3 2026	AKBA Akebia Therapeutics	-$0.0360	-$0.04	-$0.0040	-$0.05	$46.94 million	$36.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
AKBA Akebia Therapeutics	0.63	1.36	1.35
ANL Adlai Nortye	0.04	9.55	N/A
SIGA Siga Technologies	N/A	24.57	16.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
AKBA Akebia Therapeutics	33.92%
ANL Adlai Nortye	35.21%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	4.70%
AKBA Akebia Therapeutics	4.30%
ANL Adlai Nortye	N/A
SIGA Siga Technologies	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	8	49.88 million	74.37 million	Not Optionable
AKBA Akebia Therapeutics	194	277.66 million	265.72 million	Optionable
ANL Adlai Nortye	109	64.40 million	N/A	Not Optionable
SIGA Siga Technologies	49	71.86 million	69.89 million	Optionable

ANL, AKBA, SIGA, and AEON Headlines

Recent News About These Companies

SIGA Technologies stock faces longer US wait as Edison trims valuation

November 12 at 10:34 PM | ad-hoc-news.deA

SIGA Technologies, Inc. Q3 2026 Earnings Call Summary

November 10 at 1:35 PM | finance.yahoo.com

Transcript : SIGA Technologies, Inc., Q3 2026 Earnings Call, Nov 09, 2026

November 10 at 3:34 AM | marketscreener.comM

SIGA Technologies, Inc. (SIGA) Q3 2026 Earnings Call Transcript

November 10 at 1:00 AM | seekingalpha.com

SIGA Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

November 9, 2026 | marketscreener.comM

What Siga Technologies (SIGA) Said on Its Q3 Earnings Call

November 9, 2026 | marketbeat.com

SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.

November 9, 2026 | finance.yahoo.com

SIGA Technologies stock gets new Canadian TPOXX contract

October 30, 2026 | ad-hoc-news.deA

SIGA to Host Business Update Call on November 9, 2026, Following Release of Third-Quarter 2026 Financial Results

October 29, 2026 | globenewswire.com

SIGA Wins Canadian Defence Contract Worth Up To $15M For Smallpox Antiviral; Stock Up

October 28, 2026 | rttnews.com

SIGA Technologies, Inc. Secures Contract from Public Services and Procurement Canada to Supply Oral Tpoxx to Canadian Department of National Defence

October 28, 2026 | marketscreener.comM

SIGA secures $15M contract from Canadian Department of National Defence

October 28, 2026 | seekingalpha.com

SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®

October 28, 2026 | globenewswire.com

Siga Technologies (NASDAQ:SIGA) Shares Cross Above 50-Day Moving Average - Here's What Happened

October 28, 2026 | marketbeat.com

SIGA targets 2027 FDA filing: what it means for SIGA stock

October 21, 2026 | ad-hoc-news.deA

SIGA targeted a 2027 FDA filing: what it means for SIGA stock

October 16, 2026 | ad-hoc-news.deA

SIGA Technologies stock reports USD 41 million Q2 revenue

October 5, 2026 | ad-hoc-news.deA

SIGA Technologies stock holds value as small cap metrics guide investors

September 22, 2026 | ad-hoc-news.deA

SIGA Technologies stock gains on solid Q2 earnings and cash position

September 20, 2026 | ad-hoc-news.deA

NASDAQ Composite Index-Wert SIGA Technologies-Aktie: So viel hätten Anleger mit einem Investment in SIGA Technologies von vor einem Jahr verloren

September 8, 2026 | finanzen.netF

SIGA Tech (SIGA): Profits Drop 65%, But Cash and Special Payouts Remain

September 6, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANL, AKBA, SIGA, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.16 +0.00 (+1.45%)

As of 10:35 AM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Akebia Therapeutics NASDAQ:AKBA

$0.48 -0.02 (-3.01%)

As of 10:36 AM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Adlai Nortye NASDAQ:ANL

$10.14 -0.38 (-3.61%)

As of 10:36 AM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Siga Technologies NASDAQ:SIGA

$2.84 -0.05 (-1.56%)

As of 10:36 AM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANL, AKBA, SIGA, and AEON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANL, AKBA, SIGA, and AEON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANL, AKBA, SIGA, and AEON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANL, AKBA, SIGA, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

Akebia Therapeutics NASDAQ:AKBA

Adlai Nortye NASDAQ:ANL

Siga Technologies NASDAQ:SIGA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANL, AKBA, SIGA, and AEON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANL, AKBA, SIGA, and AEON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANL, AKBA, SIGA, and AEON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANL, AKBA, SIGA, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

Akebia Therapeutics NASDAQ:AKBA

Adlai Nortye NASDAQ:ANL

Siga Technologies NASDAQ:SIGA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools